Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers

Area of Science:

• Oncology
• Immunology
• Vaccine Development

Background:

• Human Epidermal growth factor Receptor 2 (HER2) is crucial in epithelial transformation and overexpressed in various cancers, making it a therapeutic target.
• Passive immunotherapies like Trastuzumab face challenges including resistance, cost, and side effects, necessitating active immunotherapy alternatives.
• Active immunotherapies, particularly DNA vaccination, present a desirable approach for sustained anti-HER2 immune responses.

Purpose of the Study:

• To develop novel active immunotherapies against HER2 by designing DNA vaccines.
• To overcome mechanisms of tolerance and immunosuppression that limit antitumor immune responses.
• To identify immunogenic HER2 epitopes for effective cancer vaccine design.

Main Methods:

• Development of DNA vaccines encoding human/rat chimeric forms of HER2 to bypass peripheral tolerance.
• Preclinical evaluation of these chimeric DNA vaccines in cancer-prone mouse models.
• Assessment of vaccine-induced immune responses and antitumor efficacy.

Main Results:

• Chimeric DNA vaccines encoding HER2 successfully circumvented peripheral tolerance in preclinical models.
• Demonstrated efficacy of anti-HER2 DNA vaccination in transgenic mice that model human breast cancer.
• Preclinical data support the rationale for clinical investigation of these novel vaccines.

Conclusions:

• Chimeric HER2 DNA vaccines represent a promising strategy for active cancer immunotherapy.
• These vaccines have the potential to induce long-lasting antitumor immunity and prevent tumor recurrence.
• Ongoing Phase I clinical trial (EudraCT 2011-001104-34) is evaluating the safety and immunogenicity of these vaccines in patients.